Alexandria Venture Investments
Alexandria Venture Investments is a venture capital firm that develops the work in real estate technology, and healthcare sectors.
Business Model:
Revenue: $2.6B
Employees: 501-1,000
Rankings
Industries / Tags:
Detailed Alexandria Venture Investments Information
Geographic Data
Address: 26 North Euclid Avenue
City: Pasadena
State: CA
Zip: 91101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$5B
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company&s;s strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Contact Phone:
+16265780777
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 6/2022 | Dren Bio | Series B | 0 |
| 1/2022 | Avalo | Convertible Note | 750k |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 7/2019 | X-Vax Technology | Series A | 0 |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 7/2020 | Vor Biopharma | Series B | 0 |
| 4/2021 | Alloy Therapeutics | Series C | 75M |
| 4/2021 | SeQure DX | Series A | 0 |
| 9/2018 | Epic Sciences | Series E | 0 |
| 1/2021 | Myeloid Therapeutics | Series A | 50M |
| 1/2019 | Frequency Therapeutics | Series B | - |
| 1/2021 | Encodia | Series C | 75M |
| 9/2022 | Novome | Series B | 0 |
| 7/2021 | Wugen | Series B | 0 |
| 10/2019 | Molecular Assemblies | Series A | 0 |
| 4/2017 | Arsanis | Series D | 0 |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 1/2019 | Immusoft | Series B | 0 |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 3/2022 | Umaro Foods | Seed Round | 0 |
| 1/2020 | TwinStrand Biosciences | Series A | 16M |
| 10/2021 | Immunai | Series B | 215M |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
| 9/2022 | Tavros Therapeutics | Seed Round | 7.5M |
| 3/2022 | Eclipse Bioinnovations | Series A | 14M |
| 10/2021 | Crop Enhancement | Convertible Note | - |
| 1/2020 | Novome Biotechnologies | Series A | 0 |
| 9/2021 | Kytopen | Series A | 0 |
| 9/2018 | BlueLight Therapeutics | Series C | 20M |
| 8/2021 | Humacyte | PIPE | 175M |
| 5/2021 | Inari | Series D | 0 |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 12/2017 | Aura Biosciences | Series C | 0 |
| 6/2021 | TRex Bio | Series A | 59M |
| 5/2021 | Invaio Sciences | Series C | 88.9M |
| 3/2019 | Cardea Bio | Series A | 7.8M |
| 4/2023 | Function Oncology | Series A | 28M |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 9/2020 | Korro Bio | Series A | 0 |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 5/2018 | Celsius Therapeutics | Series A | 65M |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 12/2018 | Kallyope | Series B | 21M |
| 8/2018 | Inari | Series B | 40M |
| 2/2022 | Harpe Bio | Venture Round | 3M |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 11/2022 | Haystack Oncology | Series A | 56M |
| 7/2021 | Axonis Therapeutics, Inc. | Venture Round | 0 |
| 12/2020 | Faze Medicines | Series A | 81M |
| 2/2022 | Harpe Bio | Convertible Note | 3.2M |
| 3/2019 | Gencove | Seed Round | 3M |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 8/2021 | Thryv Therapeutics | Series A | 0 |
| 7/2021 | Deep Genomics | Series C | 0 |
| 7/2017 | Rodeo Therapeutics | Series A | 5.9M |
| 3/2017 | EGenesis | Series A | 0 |
| 6/2021 | ImmuneID | Series A | 0 |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 3/2017 | Boragen | Series A | 10M |
| 2/2023 | Paratus Sciences | Series A | 0 |
| 11/2021 | Fountain Therapeutics | Series A | 0 |
| 3/2020 | Kallyope | Series C | 112M |
| 7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 12/2022 | SonoThera | Series A | 0 |
| 10/2017 | Visterra | Series C | 0 |
| 11/2018 | Caraway Therapeutics | Series A | 23M |
| 5/2018 | Insitro | Series A | 100M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 9/2017 | LifeMine Therapeutics | Series A | 0 |
| 6/2018 | StrideBio | Series A | 15.7M |
| 11/2021 | GeneCentric Therapeutics | Series B | 0 |
| 12/2019 | Jasper Therapeutics | Series A | 35M |
| 5/2023 | Ten63 Therapeutics | Series A | 0 |
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 7/2017 | Evelo Biosciences | Series B | 50M |
| 10/2017 | Cydan | Venture Round | 34M |
| 7/2021 | IgGenix | Series A | 0 |
| 7/2019 | GNS Healthcare | Series D | 23M |
| 3/2022 | Creyon Bio | Series A | 0 |
| 9/2018 | MouSensor | Seed Round | 3.3M |
| 9/2018 | OncoResponse | Series B | 40M |
| 6/2020 | Element Biosciences | Series B | 30M |
| 1/2019 | Dewpoint Therapeutics | Series A | 60M |
| 2/2019 | Applied Therapeutics | Series B | 0 |
| 1/2021 | AltPep | Series A | 23.1M |
| 6/2023 | AltPep | Series B | 0 |
| 10/2022 | Matchpoint Therapeutics | Series A | 70M |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 4/2021 | Molecular Assemblies | Series A | 0 |
| 10/2019 | Verseau Therapeutics | Equity | 50M |
| 1/2017 | Halio | Series C | 65M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 12/2020 | Remix Therapeutics | Series A | 65M |
| 11/2019 | Genetron Health | Series D | 71M |
| 9/2018 | ENB Therapeutics | Series A | 8.1M |
| 5/2018 | Nohla Therapeutics | Series B | 45M |
| 4/2018 | QurAlis | Seed Round | - |
| 1/2023 | Melonfrost | Seed Round | 7M |
| 5/2021 | Marvin | Seed Round | 0 |
| 2/2017 | Applied Therapeutics | Series A | 6.1M |
| 7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
| 10/2021 | Soli Organic | Venture Round | 0 |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 11/2019 | miRecule | Seed Round | 0 |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 5/2021 | miRecule | Venture Round | 0 |
| 1/2019 | Greenlight Biosciences | Venture Round | 50M |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 9/2019 | Boundless Bio | Series A | 46.4M |
| 3/2022 | Affini-T Therapeutics | Venture Round | 0 |
| 3/2017 | Antiva Biosciences | Series C | 22M |
| 10/2021 | DNA Script | Series C | 0 |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 11/2022 | Cajal Neuroscience | Series A | 96M |
| 9/2018 | Silverback Therapeutics | Series A | 37.5M |
| 11/2018 | Ribometrix | Series A | 30M |
| 1/2018 | Skyhawk Therapeutics | Seed Round | 8M |
| 6/2018 | Cibus | Series C | 70M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 12/2021 | Ambys Medicines | Series A | 47M |
| 6/2021 | Senda Biosciences | Series B | 0 |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 4/2019 | Insitro | Series A | 100M |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 9/2021 | Disc Medicine | Series B | 90M |
| 2/2021 | Ensoma | Series A | 0 |
| 8/2018 | Magnolia NeuroSciences | Series A | 0 |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 9/2021 | Asher Bio | Series B | 0 |
| 3/2019 | Imara | Series B | 0 |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 10/2019 | Variant Bio | Series A | 24.7M |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 7/2018 | ORIG3N | Series B | 0 |
| 5/2023 | Myeloid Therapeutics | Series B | 0 |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 12/2020 | Vigil Neuroscience | Series A | 50M |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 5/2023 | Myeloid Therapeutics | Series A | 0 |
| 5/2021 | BioTheryX | Series E | 92M |
| 6/2021 | Neurona Therapeutics | Venture Round | 0 |
| 7/2018 | Antiva Biosciences | Series C | 15M |
| 10/2020 | Dren Bio | Series A | 0 |
| 5/2021 | Advanced Animal Diagnostics | Series E | 0 |
| 10/2017 | Ribometrix | Seed Round | 7.5M |
| 1/2021 | Blacksmith Medicines | Seed Round | - |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 8/2022 | Senda Biosciences | Series C | 123M |
| 3/2021 | StrideBio | Series B | 0 |
| 3/2020 | Redpin Therapeutics | Series A | 15.5M |
| 1/2023 | Ensoma | Series B | 0 |
| 7/2017 | Compass Therapeutics, Inc. | Series A | - |
| 3/2018 | TCR2 | Series B | 0 |
| 2/2018 | Quentis | Series A | 48M |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 12/2017 | Metacrine | Series B | 22M |
| 3/2022 | TRex Bio | Series A | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 2/2022 | Kallyope | Series D | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 1/2022 | Korro Bio | Series B | 0 |
| 1/2021 | Senti Biosciences | Series B | 105M |
| 12/2021 | NextVivo | Venture Round | 7.9M |
| 12/2022 | Dantari | Series A | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 6/2023 | Bitterroot Bio | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 1/2019 | Tiburio Therapeutics | Series A | 31M |
| 3/2020 | Affinia Therapeutics | Series A | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 9/2018 | Benson Hill | Series C | 65M |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 2/2022 | Terray Therapeutics | Series A | 0 |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 1/2021 | Vera Therapeutics | Series C | 0 |
| 11/2022 | Rezo | Series A | 0 |
| 6/2018 | Skyhawk Therapeutics | Venture Round | 0 |
| 3/2020 | Silverback Therapeutics | Series B | 0 |
| 4/2021 | Boundless Bio | Series B | 105M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 9/2018 | System1 Biosciences | Series A | 25M |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 3/2021 | Insitro | Series C | 400M |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2018 | NextCure | Series B | 93M |
| 10/2021 | Deka Biosciences | Series A | 0 |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 2/2018 | Kallyope | Series B | 66M |
| 7/2020 | Vesigen Therapeutics | Series A | 28.5M |
| 10/2019 | Adaptive Phage Therapeutics | Venture Round | 7M |
| 12/2017 | Obsidian Therapeutics | Series A | 0 |
| 9/2021 | Acrigen Biosciences | Seed Round | - |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
